SequelSEC

Medicus Pharma Ltd. MDCX

Pharmaceutical Preparations · CIK 0001997296 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
-$34.36M
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

Medicus Pharma Ltd. (MDCX) reported net income of -$47.28M for the fiscal year ended 2025-12-31. This page shows 3 annual periods of income statement, balance sheet and cash flow figures normalized from Medicus Pharma Ltd.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Medicus Pharma Ltd. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
RevenueUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailable
Operating income-$34.36M-$11.18M-$4.73M
Net income-$47.28M-$11.16M-$5.31M
Research & development$7.72M$3.53M$193.58K
Weighted-average diluted sharesshares 17.28Mshares 9.62Mshares 3.48M
Pretax incomeUnavailableUnavailableUnavailable
Income tax expense$0$0$0
Diluted EPS$-2.74$-1.16$-1.53
Selling, general & administrativeUnavailableUnavailableUnavailable
General & administrative$17.92M$7.65M$4.54M
Selling & marketingUnavailableUnavailableUnavailable

Balance

Medicus Pharma Ltd. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
Cash & equivalents$8.71M$4.16M$1.72M
Total assets$10.06M$5.65M$1.89M
Current assets$9.89M$5.38M$1.89M
Total liabilities$10.02M$2.51M$781.61K
Current liabilities$9.94M$2.31M$781.61K
Total equity incl. NCI$37.31K$3.13M$1.11M
Temporary (mezzanine) equityUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailable
Accounts payable$3.44M$1.28M$210.84K

Cash flow

Medicus Pharma Ltd. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
Operating cash flow-$22.78M-$10.25M-$4.16M
Capital expendituresUnavailableUnavailableUnavailable
Investing cash flow-$4.62M$0Unavailable
Financing cash flow$31.94M$12.69M$5.61M
Net change in cash$4.54M$2.44MUnavailable
Stock-based compensation$1.51M$713.12K$98.58K
Common dividends paidUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailable

Derived

Medicus Pharma Ltd. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
Free cash flowUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailable
Current ratio1.00x2.33x2.42x
Revenue YoY growthUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open MDCX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-12View SEC filing
10-Q · Filed 2026-05-14View SEC filing
10-K · Filed 2026-03-25View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-08-11View SEC filing
10-Q · Filed 2025-05-12View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.